CSIMarket Company Name, Ticker, Industry, else..
 
Xbiotech Inc   (NASDAQ: XBIT)
Other Ticker:  
 
 
Price: $3.5000 $0.08 2.339%
Day's High: $3.45 Week Perf: 11.46 %
Day's Low: $ 3.45 30 Day Perf: 15.51 %
Volume (M): 1 52 Wk High: $ 9.96
Volume (M$): $ 2 52 Wk Avg: $6.27
Open: $3.45 52 Wk Low: $2.94



 Market Capitalization (Millions $) 107
 Shares Outstanding (Millions) 31
 Employees 22
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -39
 Cash Flow (TTM) (Millions $) -27
 Capital Exp. (TTM) (Millions $) 1

Xbiotech Inc
Xbiotech Inc is a biopharmaceutical company based in Austin, Texas. The company focuses on the discovery, development, and commercialization of antibody therapies for various diseases. Xbiotech's main therapeutic approach involves harnessing the power of the immune system to fight diseases including cancer, infectious diseases, and inflammatory conditions. The company has an established pipeline of monoclonal antibody candidates and has received approval for some of its products in Europe. Xbiotech Inc is committed to advancing innovative treatments and improving patient outcomes.


   Company Address: 5217 Winnebago Ln Austin 78744 TX
   Company Phone Number: 386-2900   Stock Exchange / Ticker: NASDAQ XBIT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        0.31% 
BMY   -0.35%    
JNJ   -0.03%    
MRK   -0.74%    
PFE        2.35% 
SNY        2.46% 
• View Complete Report
   



Clinical Study

Healthcare Workforce Management Market Hits $1.7B in 2024, Surging to $2.8B by 2029 with a 10.1% CAGR | MarketsandMar...

Published Wed, Jun 19 2024 12:30 PM UTC

Revolutionizing Healthcare Workforce Management: Market to Reach $2.8B by 2029 The healthcare workforce management systems market has shown remarkable growth over recent years, with projections indicating substantial future expansion. In 2024, the market valuation reached $1.7 billion and is anticipated to soar to $2.8 billion by 2029. This growth translates to a significan...
Clinical Study

XBiotechs Innovative Combination Therapy Shows Potential Breakthrough in Advanced Pancreatic Cancer Treatment ...

Published Tue, Jun 18 2024 3:35 PM UTC

Potential Breakthrough in Pancreatic Cancer Treatment Emerges from XBiotech s Phase 1/2 StudyPancreatic cancer remains one of the most formidable oncological challenges, characterized by late-stage diagnosis and poor prognosis. However, a recent randomized double-blinded Phase 1/2 study conducted by XBiotech has yielded results that hint at a promising advancement in treati...
Xbiotech Inc

XBiotech Inc. Reports Operating Deficit of $-10.853 Million, Plans State-of-the-Art Research Facility in Austin, Texas

Investors in XBiotech Inc. have been closely monitoring the company's performance during the earnings season of January to March 31, 2024. While top-line adjustments were not expected, there has been a notable increase in the company's operating deficit, which came in at $-10.853 million during this period.
Despite this setback, XBiotech Inc. recently announced plans to construct a state-of-the-art research and development facility in Austin, Texas. This expansion highlights the company's dedication to innovation and growth in the biotechnology industry. With research and development being crucial to the success of biotech companies, this new facility is expected to drive XBiotech to new heights.
In terms of stock performance, XBiotech Inc. has seen a solid gain of 9.41% over the last five trading days and a 8.15% increase during the second quarter of 2024. The stock is currently trading on the NASDAQ at 64% above its 52-week average, showcasing strong investor confidence in the company's future prospects.
Xbiotech Inc

XBITsn Holds Steady Revenue in Fourth Quarter of 2023

Xbiotech Inc., a leading biotechnology company, recently released its financial results for the fiscal period ending December 31, 2023. The company reported a loss of $0.15 per share, compared to $0.10 per share the previous year, while Income per Share improved from $0.24 to $0.00 per share from the previous quarter. Despite the losses, the company remains optimistic about its future growth prospects.
One interesting fact from the financial report is that Xbiotech Inc. realized a net shortfall of $4.635 million, which is higher than the $3.203 million reported a year ago. Additionally, the company also noted a shortfall of $24.56 million for the financial period 2023. Despite these challenges, the company is committed to innovation and advancing the frontiers of medical science.
Product Service News

XBiotech Unveils Ambitious Plans for State-of-the-Art R&D Facility, Bolstering Innovation in Biotechnology

Published Thu, Jan 4 2024 2:03 PM UTC

XBiotech Inc., a leading biotechnology company based in Austin, Texas, has set its sights on significant growth with the announcement of plans to construct a state-of-the-art research and development facility. The company has received approval from the City of Austin and is set to commence excavation and site preparation for this groundbreaking project in the first quarter o...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com